Abstract
This chapter focuses on the Chemistry, Manufacturing, and Controls (CMC) from the scientific and regulatory perspective of the development of poorly water-soluble drugs to provide insights into regulatory filing from Investigational New Drug Application (IND) to New Drug Application (NDA) submission. The chapter includes two primary sections to cover the two regulatory stages for CMC module of filing, IND and NDA. The IND section of the chapter includes the following contents: (1) brief description of general filing requirements as outlined in the Code of Federal Regulations (CFR) and relevant guidances; (2) discussion of potential regulatory issues for developing poorly water-soluble drugs using various pharmaceutical technologies in the IND stage, i.e., solid-form selection, particle-size reduction, lipid formulation, and amorphous solid dispersion. The NDA section of the chapter includes the following: (1) general regulatory filing requirements of an NDA application; (2) potential regulatory issues associated with poorly water-soluble drugs; detailed discussions are carried out on topics including solid-form selection of the drug substance, drug product development using novel pharmaceutical technologies, development of control strategies, etc.; (3) case studies of marketed drug products of poorly water-soluble drugs in various dosage forms; this part uses the public information of the approved products as examples to support the discussions as outlined in part (2); and (4) brief discussion on the concept of Biopharmaceutics Classification System (BCS) in the development of poorly soluble drugs. The book chapter concludes with a brief summary which emphasizes on the link between regulation and science.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Drug substance means an active ingredient that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates use in the synthesis of such ingredient (21 CFR 314.3(b)).
- 2.
Drug product means a finished dosage form, for example, tablet, capsule, or solution, that contains a drug substance, generally, but not necessarily, in association with one or more other ingredients (21 CFR 314.3(b)).
- 3.
Active also refers to drug substance.
References
Amidon GL, Lennernaes H, Shah VP et al (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413–420
Bauer J, Spanton S, Henry R et al (2001) Ritonavir: an extraordinary example of conformational polymorphism. Pharm Res 18:859–866
Bawa R (2009) Nanopharmaceuticals for drug delivery—a review. Drug Deliv 3:122–127
Borchardt RT, Kerns EH, Lipinski CA et al (eds) (2004) Pharmaceutical profiling in drug discovery for lead selection. American Association of Pharmaceutical Scientists, Arlington, TX
Brittain HG (ed) (2009) Polymorphism in pharmaceutical solids, 2nd edn. Informa Healthcare, New York
Canon JB (2008) Chemical and physical stability considerations for lipid-based drug formulations. Am Pharm Rev 11(132):134–138
Chemburkar SR, Bauer J, Deming K et al (2000) Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development. Org Process Res Dev 4:413–417
Cuine JF (2009) Lipid-based oral drug delivery systems to enhance solubility and absorption of poorly water-soluble drugs. Am Pharm Rev 12:74–83
Dubin CH (2006) Formulation strategies for poorly soluble drugs. Drug Deliv Technol 6:34–38
Dunitz JD, Bernstein J (1995) Disappearing polymorphs. Acc Chem Res 28:193–200
FDA (1989) Guideline for drug master files. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122886.htm. Accessed 1 Dec 2015
FDA (1995) Guidance for industry—content and format of investigational new drug applications (INDs) for Phase 1 studies of drugs, including well-characterized, therapeutic, biotechnology-derived products
FDA (1997a) Guidance for industry—dissolution testing of immediate release solid oral dosage forms
FDA (1997b) Guidance for industry—extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlation
FDA (2000) Guidance for industry—analytical procedures and methods validation
FDA (2001) Guidance for industry—M4Q: the CTD—quality
FDA (2003) Guidance for industry—INDs for Phase 2 and Phase 3 studies chemistry, manufacturing, and controls information
FDA (2010) The FDA’s drug review process: ensuring drugs are safe and effective. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143534.htm. Accessed 1 Dec 2015
FDA (2014) Guidance for industry—bioavailability and bioequivalence studies submitted in NDAs or INDs—general considerations
FDA (2015a) Guidances (Drugs). http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed 11 Nov 2015
FDA (2015b) Manual of policies and procedures (CDER). http://www.fda.gov/AboutFDA/CentersOffices/CDER/ManualofPoliciesProcedures/default.htm. Accessed 11 Nov 2015
FDA (2015c) Guidance for industry—Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system
Flinn T, Northen J, Fernandes P (2008) New drug development: getting to the optimal physical form. Pharm Chem 7:20–23
Florence AJ (2009) Approaches to high-throughput physical form screening and discovery. Drug Pharm Sci 192:139–184
Fort JJ, Krill SL, Law D et al (2000) Solid dispersion pharmaceutical formulations. US Patent 7,364,752, 10 Nov 2011
Gift AD, Luner PE, Luedeman L et al (2009) Manipulating hydrate formation during high shear wet granulation using polymeric excipients. J Pharm Sci 98:4670–4683
Guarino RA (ed) (2004) New drug approval process, 4th edn. Marcel Dekker, New York
Hou T, Xu X (2004) Recent development and application of virtual screening in drug discovery: an overview. Curr Pharm Des 10:1011–1033
Hu J, Johnston KP, Williams RO III (2004) Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev Ind Pharm 30:233–245
ICH (1996) Stability testing: photostability testing of new drug substances and products Q1B
ICH (1999) Specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances Q6A
ICH (2000) Good manufacturing practice guide for active pharmaceutical ingredients Q7
ICH (2003a) Stability testing of new drug substances and products Q1A(R2)
ICH (2003b) Evaluation for stability data Q1E
ICH (2005) Validation of analytical procedures: text and methodology Q2(R1)
ICH (2006a) Impurities in new drug substances Q3A(R2)
ICH (2006b) Impurities in new drug products Q3B(R2)
ICH (2011) Impurities: guideline for residual solvents Q3C(R5)
ICH (2015) Quality guidelines. http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html. Accessed 11 Nov 2015
ICH (2014) Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk M7
Intelence® (Etravirine) Tablets Full Prescribing Information (2010) http://www.intelence-info.com/sites/default/files/pdf/INTELENCE_Booklet_Package_Insert_hcp.pdf. Accessed 19 Oct 2015
Kobayashi Y, Ito S, Itai S et al (2000) Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int J Pharm 193:137–146
Lakshman JP, Cao Y, Kowalski J et al (2008) Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug. Mol Pharm 5:994–1002
Lang M, Kampf JW, Matzger AJ (2002) Form IV of carbamazepine. J Pharm Sci 91:1186–1190
Law D, Schmitt EA, Marsh KC et al (2004) Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluation. J Pharm Sci 93:563–570
Lehto P, Aaltonen J, Tenho M et al (2009) Solvent-mediated solid phase transformations of carbamazepine: effects of simulated intestinal fluid and fasted state simulated intestinal fluid. J Pharm Sci 98:985–996
Lipari J, Al-Razzak LA, Ghosh S et al (1997) Pharmaceutical composition. US Patent 6,232,333, 7 Nov 1997
Lipinski CA (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235–249
Liversidge GG, Cundy KC, Bishop JF et al (1991) Surface modified drug nanoparticles. US Patent 5,145,684, 25 Jan 1991
Lowe JA, Jones P, Wilson DM (2009) The importance of target validation in drug discovery and development. Curr Opin Drug Discov Devel 12:581–584
Merisko-Liversidge EM, Liversidge GG (2008) Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol 36:43–48
Merisko-Liversidge E, Liversidge GG, Cooper ER (2003) Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 18:113–120
Meyer MC, Straughn AB, Jarvi EJ et al (1992) The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm Res 9:1612–1616
Norvir® Soft Gelatin Capsule Prescribing Information (2015) http://www.rxabbvie.com/pdf/norpi2a.pdf. Accessed 19 Oct 2015
O’Neil MJ (ed) (2006) The Merck index: an encyclopedia of chemicals, drugs, and biologicals, 13th edn. Merck, Whitehouse Station, NJ
Orange Book: approved drug products with therapeutic equivalence evaluations (2015) U.S. Food and Drug Administration. Silver Spring. http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm. Accessed 19 Oct 2015
Porter CJH, Wasan KM, Constantinides P (2008) Lipid-based systems for the enhanced delivery of poorly water soluble drugs. Adv Drug Deliv Rev 60:615–616
Pouton CW (2006) Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 29:278–287
Radomska-Soukharev A (2007) Stability of lipid excipients in solid lipid nanoparticles. Adv Drug Deliv Rev 59:411–418
Radomska-Soukharev A, Mueller RH (2006) Chemical stability of lipid excipients in SLN-production of test formulations, characterization and short-term stability. Pharmazie 61:425–430
Rapamune® Oral Solution Prescribing Information (2015) http://labeling.pfizer.com/showlabeling.aspx?id=139. Accessed 19 Oct 2015
Rogge MC, Taft DR (eds) (2010) Preclinical drug development, 2nd edn. Taylor & Francis, Boca Raton
Rustichelli C, Gamberini G, Ferioli V et al (2000) Solid-state study of polymorphic drugs: carbamazepine. J Pharm Biomed Anal 23:41–54
Ryde NP, Ruddy SB (2000) Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate. US Patent 6,375,986, 21 Sep 2000
Ryde T, Gustow EE, Ruddy SB et al (2003a) Nanoparticulate fibrate formulations. US Patent 7,276,249, 23 May 2003
Ryde T, Gustow EE, Ruddy SB et al (2003b) Methods of treatment using nanoparticulate fenofibrate compositions. US Patent 7,320,802, 27 Oct 2003
Salyer KL (2009) Preclinical pharmacokinetic models for drug discovery and development. Drug Pharm Sci 186:659–673
Serajuddin ATM (1999) Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:1058–1066
Stahl PH, Sutter B (2006) Salt selection. In: Hilfiker R (ed) Polymorphism: in the pharmaceutical industry. Wiley-VCH, Weinheim
Tang B, Cheng G, Gu JC et al (2008) Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage forms. Drug Discov Today 13:606–612
Tian F, Zeitler JA, Strachan CJ et al (2006) Characterizing the conversion kinetics of carbamazepien polymorphs to the dihydrate in aqueous suspension using Raman spectroscopy. J Pharm Biomed Anal 40:271–280
Tong P, Zografi G (2004) Effects of water vapor absorption on the physical and chemical stability of amorphous sodium indomethacin. AAPS PharmSciTech 5:2
USP 38-NF 33 (2015) United States Pharmacopeia 38/National Formulary 33. United States Pharmacopeial Convention, Rockville
Verreck G, Baert L (2006) Antiviral compositions. US Patent 7,887,845, 3 Feb 2006
Waranis, RP, Leonard TW (1994) Rapamycin formulations for oral administration. US Patent 5,536,729, 9 Sep 1994
Weuts I, Van Dycke F, Voorspoels J et al (2011) Physicochemical properties of the amorphous drug, cast films, and spray dried powders to predict formulation probability of success for solid dispersions: etravirine. J Pharm Sci 100:260–274
Yang SY (2010) Pharmacophore modeling and application in drug discovery: challenges and recent advances. Drug Discov Today 15:444–450
Acknowledgement
The authors wish to thank Drs. Richard Lostritto, Christine Moore, and Stephen Moore for critically reviewing the manuscript and insightful discussions during the preparation of this book chapter.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Dong, Z., Patel, H. (2016). Scientific and Regulatory Considerations for Development and Commercialization of Poorly Water-Soluble Drugs. In: Williams III, R., Watts, A., Miller, D. (eds) Formulating Poorly Water Soluble Drugs. AAPS Advances in the Pharmaceutical Sciences Series, vol 22. Springer, Cham. https://doi.org/10.1007/978-3-319-42609-9_14
Download citation
DOI: https://doi.org/10.1007/978-3-319-42609-9_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42607-5
Online ISBN: 978-3-319-42609-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)